U.S. Markets open in 1 hr 15 mins

Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
·11 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

-- Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the Second Half Calendar 2022

-- Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start First Half Calendar 2022 with Top-Line Results Expected in the Second Half Calendar 2022

-- Vyleesi® Sales Metrics Improving - Net Sales Up 98%, Net Revenue per Prescription Dispensed Up 45%, Over Prior Quarter

-- $53.4 Million in Cash and Cash Equivalents at September 30, 2021 - Projected Cash Runway Through Calendar 2022

-- Teleconference and Webcast Today at 9:30 a.m. Eastern Time

CRANBURY, N.J., Nov. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced results for its first fiscal quarter ended September 30, 2021.

Palatin Technologies, Inc.
Palatin Technologies, Inc.

"I am excited with the significant advancement of our melanocortin agonist programs and their differentiating product profiles, which include the expected initiation of a Phase 3 pivotal study of PL9643 in patients with dry eye disease next month, and a Phase 2 clinical trial of PL8177 for ulcerative colitis in the first half of calendar year 2022," stated Carl Spana, Ph.D., President and CEO of Palatin.

"Regarding Vyleesi, our measured plan is showing positive trends for our targeted value metrics with net revenue up 98% and net revenue per prescription up 45% over the prior quarter ended June 30, 2021," concluded Dr. Spana.

Recent Highlights and Upcoming Events

  • Anti-Inflammatory / Autoimmune Programs

  • Research and Development Infrastructure: Strengthened R&D department with key appointments who have demonstrated a high-level of expertise in their fields to support the advancement of our development programs.

  • Vyleesi® (bremelanotide injection) / Hypoactive Sexual Desire Disorder (HSDD): Goal of the Vyleesi program is to demonstrate product value in the marketplace with an objective of re-licensing the U.S. rights to a committed women's healthcare company.

First Quarter Ended Fiscal Year 2022 Financial Results

Revenue

Total net revenues consist of gross product sales of Vyleesi, net of allowances and accruals.

Vyleesi gross product sales for the quarter ended September 30, 2021, amounted to $1.4 million, with net product revenue of $159,482, compared to gross product sales for the period July 25 (the date Palatin regained North American rights to Vyleesi) to September 30, 2020, of $809,100, with negative net product revenue of $(288,560).

Operating Expenses

Total operating expenses for the quarter ended September 30, 2021, were $7.4 million, compared to $3.7 million for the comparable quarter of 2020.

The increase in operating expenses was primarily due to the gain of $1.6 million (which reduced expenses) recorded during the quarter ended September 30, 2020, as a result of the Vyleesi Termination Agreement with AMAG Pharmaceuticals, and secondarily to increased commercial expenses related to Vyleesi.

Cash Flows

Palatin's net cash used in operations for the quarter ended September 30, 2021, was $6.4 million, compared to net cash provided by operations of $3.8 million for the same period in 2020. The difference is due to the cash received in excess of the gain on termination of the Vyleesi agreement with AMAG.

Net Loss

Palatin's net loss for the quarter ended September 30, 2021, was $7.1 million, or $0.03 per basic and diluted common share compared to a net loss of $3.9 million or $0.02 per basic and diluted common share for the same period in 2020.

The difference between the quarter ended September 30, 2021, and the quarter ended September 30, 2020, was primarily due to the gain of $1.6 million recorded during the quarter ended September 30, 2020, as a result of the Vyleesi Termination Agreement with AMAG Pharmaceuticals and secondarily to increased commercial expenses related to Vyleesi.

Cash Position

As of September 30, 2021, Palatin's cash and cash equivalents were $53.4 million with $0.9 million of accounts receivable, compared to cash and cash equivalents of $60.1 million with $1.6 million of accounts receivable, as of June 30, 2021.

Based on its current operating plan, Palatin believes that existing cash and cash equivalents will be sufficient to fund currently anticipated operating expenses through calendar year 2022.

Conference Call / Webcast

Palatin will host a conference call and audio webcast on November 15, 2021, at 9:30 a.m. Eastern Time to discuss the quarter ended September 30, 2021, results of operations in greater detail and provide an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-877-614-0009 (US/Canada) or 1-856-344-9283 (international), conference ID 3594800. The audio webcast and replay can be accessed by logging on to the "Investor/Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (US/Canada) or 1-719-457-0820 (international), passcode 3594800. The webcast and telephone replay will be available through November 22, 2021.

About Melanocortin Receptor Agonists and Inflammation

The melanocortin receptor ("MCr") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.

Many tissues and immune cells located in the eye (and other places, for example the gut and kidney) express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about market potential of Vyleesi and other Palatin products in development, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, market potential for product candidates, and potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, Palatin's ability to establish and maintain the capability for manufacturing, marketing and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

PALATIN TECHNOLOGIES, INC.

and Subsidiary

Consolidated Statements of Operations

(unaudited)







Three Months Ended September 30,



2021


2020







REVENUES





Product revenue, net

$ 159,482


$ (288,560)



159,482


(288,560)


OPERATING EXPENSES





Cost of products sold

53,933


25,200


Research and development

3,484,764


2,923,851


Selling, general and administrative

3,836,542


2,331,606


Gain on license termination agreement

-


(1,623,795)


Total operating expenses

7,375,239


3,656,862







Loss from operations

(7,215,757)


(3,945,422)







OTHER INCOME (EXPENSE)





Investment income

1,410


12,135


Foreign currency gain

107,359


-


Interest expense

(5,631)


(7,489)


Total other income, net

103,138


4,646







NET LOSS

$ (7,112,619)


$ (3,940,776)












Basic and diluted net loss per common share

$ (0.03)


$ (0.02)


Weighted average number of common shares
outstanding used in computing basic and diluted net
loss per common share

238,233,063


236,345,862







PALATIN TECHNOLOGIES, INC.

and Subsidiary

Consolidated Balance Sheets

(unaudited)






September 30, 2021


June 30, 2021

ASSETS




Current assets:




Cash and cash equivalents

$ 53,421,179


$ 60,104,919

Accounts receivable

914,015


1,580,443

Inventories

1,108,067


1,162,000

Prepaid expenses and other current assets

2,946,797


3,059,679

Total current assets

58,390,058


65,907,041





Property and equipment, net

140,022


94,817

Right-of-use assets

1,146,332


1,237,813

Other assets

56,916


56,916

Total assets

$ 59,733,328


$ 67,296,587





LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable

$ 762,817


$ 640,650

Accrued expenses

4,991,164


5,797,378

Short-term operating lease liabilities

353,925


351,853

Other current liabilities

3,679,852


3,721,907

Total current liabilities

9,787,758


10,511,788





Long-term operating lease liabilities

808,840


900,520

Other long-term liabilities

6,167,603


6,232,907

Total liabilities

16,764,201


17,645,215





Stockholders' equity:




Preferred stock of $0.01 par value – authorized 10,000,000 shares; shares
issued and outstanding designated as follows:




Series A Convertible: authorized 264,000 shares: issued and outstanding
4,030 shares as of September 30, 2021 and June 30, 2021

40


40

Common stock of $0.01 par value – authorized 300,000,000 shares:




issued and outstanding 231,301,673 shares as of September 30, 2021 and
230,049,691 shares as of June 30, 2021

2,313,017


2,300,497

Additional paid-in capital

399,564,086


399,146,232

Accumulated deficit

(358,908,016)


(351,795,397)

Total stockholders' equity

42,969,127


49,651,372

Total liabilities and stockholders' equity

$ 59,733,328


$ 67,296,587





Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-reports-first-quarter-fiscal-year-2022-results-and-provides-corporate-update-301423576.html

SOURCE Palatin Technologies, Inc.